DeepMed Research

Amantadine

Generic Name: Amantadine

Brand Names: Gocovri, Osmolex

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₇N

CAS Number: 768-94-5

Unique Ingredient Identifier: BF4C9Z1J53

Background: An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.

Indication: For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Associated Conditions: Dyskinesia, Extrapyramidal disorder caused by neuroleptic drugs without Tardive dyskinesia, Influenza A Virus Infection, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Parkinsonism

Clinical Trials

Changes in Glutamatergic Neurotransmission of Severe TBI Patients

Early Phase 1

Suspended

Conditions: Traumatic Brain Injury
Disorder of Consciousness

Interventions: Drug: Amantadine + L-DOPA
Drug: NMDA blocker

First Posted Date: 2020-01-28

Last Posted Date: 2022-09-30

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 30

Registration Number: NCT04244058

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Evaluation of the Effect of Preoperative Intravenous Amantadine Sulfate on the Postoperative Early Cognitive Functions in a Elderly Patient With Laparoscopic Radical Prostatectomy

Phase 4

Conditions: Postoperative Cognitive Dysfunction

Interventions: Drug: Amantadine Sulfate
Drug: Placebo (for amantadine sulphate)

First Posted Date: 2019-06-17

Last Posted Date: 2019-06-20

Lead Sponsor: TC Erciyes University

Target Recruit Count: 54

Registration Number: NCT03988010

Locations: 🇹🇷
Erciyes Univercity, Kayseri, Melikgazi, Turkey

Oral Amantadine, IV Amantadine and Hemodynamic Response to Laryngoscopy

Phase 2

Conditions: Intubation, Intratracheal

Interventions: Drug: placebo tablet
Drug: i.v Amantadine Sulfate
Drug: oral Amantadine sulfate

First Posted Date: 2018-08-02

Last Posted Date: 2021-11-16

Lead Sponsor: Assiut University

Target Recruit Count: 60

Registration Number: NCT03612921

Locations: 🇪🇬
Assiut university hospitals, Assiut, Egypt

Effects of Amantadine on Postoperative Cognitive Dysfunction

Not Applicable

Conditions: Postoperative Cognitive Dysfunction

Interventions: Drug: Amantadine

First Posted Date: 2018-05-17

Last Posted Date: 2019-01-03

Lead Sponsor: Zhiyi Zuo

Target Recruit Count: 390

Registration Number: NCT03527134

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China

Benefits of Amantadine in Patients With Coma State

Conditions: Coma; Prolonged
Amantadine

Interventions: Drug: amantadine sulphate

First Posted Date: 2018-02-22

Last Posted Date: 2018-09-06

Lead Sponsor: Dokuz Eylul University

Target Recruit Count: 56

Registration Number: NCT03443037

Locations: 🇹🇷
Dokuz Eylul University, Izmir, Turkey

Citicholine-Amantadine Trial in Traumatic Brain Injury

Phase 4

Completed

Conditions: Intensive Care Unit

Interventions: Drug: Citicholine
Drug: Amantadine

First Posted Date: 2018-02-13

Last Posted Date: 2024-05-24

Lead Sponsor: Ain Shams University

Target Recruit Count: 45

Registration Number: NCT03430817

Locations: 🇪🇬
Ain Shams University hospitals, Cairo, Egypt

Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis

Phase 3

Completed

Conditions: Fatigue in Multiple Sclerosis

Interventions: Drug: Amantadine
Drug: Modafinil
Drug: Methylphenidate
Drug: Placebos

First Posted Date: 2017-06-14

Last Posted Date: 2020-10-20

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 141

Registration Number: NCT03185065

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Amantadine and Functional Improvement Following ABI Measured by MRI Tractography; A Pilot Study

Not Applicable

Conditions: Coma
Persistent Vegetative State
Acquired Brain Injury
Traumatic Brain Injury
Minimally Conscious State

Interventions: Drug: Amantadine
Procedure: MRI Tractography Study

First Posted Date: 2015-10-02

Last Posted Date: 2015-12-11

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 10

Registration Number: NCT02566720

Locations: 🇨🇦
Hamilton Health Sciences, Hamilton, Ontario, Canada

Amantadine to Speed Awakening After Cardiac Arrest

Phase 2

Completed

Conditions: Heart Arrest
Coma
Anoxia

Interventions: Drug: Placebo
Drug: Amantadine

First Posted Date: 2015-07-01

Last Posted Date: 2019-12-04

Lead Sponsor: Jon Rittenberger, MD

Target Recruit Count: 14

Registration Number: NCT02486211

Locations: 🇺🇸
Main Medical Center, Portland, Maine, United States
🇺🇸
Beth Israel Deacconness, Boston, Massachusetts, United States
🇺🇸
UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States

and more 1 locations

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Phase 2

Completed

Conditions: Walking Impairment
Multiple Sclerosis

Interventions: Drug: ADS-5102
Other: Placebo

First Posted Date: 2015-06-15

Last Posted Date: 2017-08-08

Lead Sponsor: Adamas Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT02471222

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy